**Streptomyces Levis ABRIINW111 Inhibits SW480 Cells Growth by Apoptosis Induction**

Behnaz Faramarzian Azimi Maragheh1,2, Parisa Fatourachi3, Seyede Momeneh Mohammadi1, Behnaz Valipour4, Meysam Behzadi5, Alireza Dehnad2,*, Hojjatollah Nozad Charoudeh1,2*

1 Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

2 Tabriz Higher Education Institute of Rab-Rashid, Department of Biological Sciences, Tabriz, Iran.

**Abstract**

**Purpose:** Streptomyces sp., a dominant genus in Actinomycetes, is the source of a wide variety of secondary metabolites. Microbial metabolites can be utilized as novel anticancer agents; with fewer side effects. The present article illustrated the anti-caricinogenic effect of the other extracted organic metabolites derived from *Streptomyces* bacteria on SW480 colon cancer cell line.

**Methods:** MTT assay was performed in order to investigate the cytotoxicity effect of metabolites on SW480 cells. Apoptosis and cell cycle arrests were measured by flowcytometry. Morphological changes were indicated by Propidium iodide staining and P53 gene expression was evaluated by real-time PCR.

**Results:** *Streptomyces Levis ABRIINW111* inhibited cell growth, increased Caspases 3 and reduced Ki67 expression in a concentration/time-dependent manner in SW40 cells. Metabolites increased subG1 phase (apoptosis) and also cell cycle arrest in G1, G2/M and S phase. P53 gene expression followed SW40 cells treatment significantly.

**Conclusion:** *Streptomyces sp.* metabolites have anti-caricinogenic effect on colon cancer cells. *Streptomyces Levis ABRIINW111* metabolites are a candidate for Colon cancer treatment.

**Introduction**

Colon cancer is one of the most prevalent malignancies in the world.1,2 Neoplastic cells reduced normal growth and exhibit abnormal cell cycle. Sporadic and somatic genes mutations are mostly involved in colon cancer.3,4 It was indicated that natural products are able to induce apoptosis in cancer cells without serious side effects.5 Over the decades, considerable efforts were put into the use of natural products as the anticancer agents against various types of cancers in order to activate cell death signals in cancer cells.6 Previous studies have shown that natural products have therapeutic effects such as anti-cancer and anti-infection activity.7 Actinomycetes are the best source of bioactive secondary metabolites for utilizing in drug discovery and biotechnology.8 *Streptomyces* is a dominant genus in Actinomycetes, which is the source of 80% of the produced bioactive secondary metabolites.9 For example, Rapamycin-isolated from the soil bacteria; *Streptomyces hygroscopicus-* is an anticancer agent which induces apoptosis and cell cycle arrest. Metabolites of *Streptomyces sp. SY-103* have strong cytotoxic effects which induce apoptosis in human leukemia cells through the activation of caspase3 and inactivation of Akt signaling.10,11 Recently, it was indicated that either extracted metabolites of *Streptomyces Levis ABRIINW111* have anti-caricinogenic effects on colon cancer12 as well. Apoptosis was used as a target for cancer therapy and several drugs were designed to activate Caspase family.13 Caspases family are the key elements in apoptosis and are influenced by both intrinsic and extrinsic pathways.14 P53 is one of the most important genes in apoptosis which has a critical role in cell cycle.15 It can cause cell cycle arrest in certain stages of cell cycle by up regulation of both P21 and P27 protein that consequently inhibits all cyclin–CDK complexes and can result in apoptosis.16

In the present study, a new strain of *Streptomyces* - isolated from the Zagros Mountains Hamadan in Iran is reported. The mentioned strain produced secondary metabolites against gram positive and gram negative bacteria.17 Based on GeneBank data-base-, there is 98% similarity between 16S rDNA gene and S. Levis strain NRRL B-16370. Bergey’s manual of systematic bacteriology strongly suggested that morphology properties of strain *ABRIINW111* belonged to the genus *Streptomyces*.17 The extracted metabolites had anti-cancer effect on Colon cancer by cell growth inhibition.

**Keywords:**

- Anti-Cancer
- Colon cancer
- Metabolites
- Streptomyces
- SW480

---

1*Corresponding author: Hojjatollah Nozad Charoudeh and Alireza Dehnad, Tel/Fax: +98 41 33363870, Email: nozadh@tbzmed.ac.ir, Tel/Fax: +98 41 35405674, Email: a.dehnad@areeo.ac.ir

2©2018 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
arresting cell cycle, inducing apoptosis and by increasing P53 expression in Colon cancer.

**Materials and Methods**

**Microbial culture and Fermentation**

*Streptomyces Levis ABRIINW111* strain -isolated from soil samples- was extracted in the Department of Microbial Biotechnology, AREEO, Tabriz, Iran and was cultured in Nutrient Agar medium (70148, Sigma, Germany) at 29 °C for 7 days. The loops full of bacteria were inoculated into 25 ml of Mueller Hinton Broth medium (70192, Sigma, Germany) and incubated while agitating on shaker incubator set as 70 rpm at 29 °C for 36 h. After fermentation time, 1 ml of pre-culture was applied to inoculate 1,000-ml Erlenmeyer flasks, each containing 150 ml of fresh Mueller Hinton Broth medium. The fermentation was done at 29 °C for 7 days on shaker incubator set as 70 rpm, centrifuged at 4000 rpm for 20 min. The Cell free filtrate was mixed with equal volume of Diethyl ether (1:1 V/V) shaken for 10 min at 175 rpm, extracted by Diethyl ether (100921, Merck, USA), by the use of separating funnel. Finally, the obtained organic extract was undertaken to be concentrated at room temperature to achieve 0.01 gr crude extract which was maintained at 4 °C until being utilized. As previously described, the turbidity 620 nm, 0.08 O.D. was considered appropriate for inoculation.

**Metabolites analysis with HPLC method**

Extracted metabolites were analyzed by HPLC method. The column system consisted of a C18 column, UV detector and 215 nm wave lengths. Dried metabolites were dissolved in acetonitrile. The mobile phase consisted of methanol, H2O and acetonitrile (45, 50, 5). Injected metabolites were 1 µl and the flow rate was set as 1 ml min⁻¹ for 10 min. Peak responses were measured at 215 nm. (Figure 1)

![UV Detector](image)

**Results**

| Retention time | Area       | Area%  | Height    | Height%  |
|----------------|------------|--------|-----------|----------|
| 1.567          | 568848     | 23.66  | 62649     | 20.46    |
| 1.883          | 207809     | 8.64   | 38546     | 12.59    |
| 2.033          | 383679     | 15.96  | 38954     | 12.72    |
| 2.233          | 233759     | 9.72   | 33517     | 10.94    |
| 2.433          | 197992     | 8.23   | 20018     | 6.54     |
| 2.617          | 104875     | 4.36   | 17382     | 5.68     |
| 2.783          | 79826      | 3.32   | 12054     | 3.94     |
| 3.050          | 627710     | 26.11  | 83139     | 27.15    |

*Figure 1. HPLC Chromatogram of Diethyl ether extracted metabolites of Streptomyces Levis ABRIINW111*

**Cell culture and MTT assay**

Colon cancer cell line, SW480, was purchased from Iran National Cell Bank (Pasteur Institute/IRAN). The cells were cultured in RPMI-1640 medium (51800-035, Gibco, USA) supplemented with 10% Fetal Bovine Serum (10270-106, Gibco, USA), 100 U ml⁻¹ Penicillin and 100 µg ml⁻¹ streptomycin (15140-122, Gibco, USA). 1x10⁴ SW480 cells were seeded per well in 96-well plates with 100µl of culture medium and were incubated for 24 h. Metabolites were diluted in culture medium with less than 0.1% DMSO (1029521000, Merck, USA) and the cells were incubated with various concentration of metabolites (100, 500, 1000, 2000 and 5000 ng ml⁻¹) for 24, 48 and 72 h. The highest concentration of DMSO was employed as positive control. After incubation time, supernatant was
**Streptomyces Levis inhibits colon cancer**

Carefully replaced with 20 μL of MTT reagent (M6494, Sigma, Germany) \(3\times(4,5\text{-dimethyl thiazol}-2\text{-yl})-2,5\text{-diphenyl tetrazolium bromide (5 mg mL}^{-1}\)) incubated at 37 °C for 4 h and 100 μL of DMSO was subsequently added to dissolve the emerged colored formazan crystals. The optical density was measured at 570 nm with a reference wavelength of 630 nm by micro plate Elisa reader (Biotek ELx 808, USA). The effect of metabolites was calculated as a percentage of treated cells/control cells. Cytotoxicity rate was expressed as IC50 value (the concentration caused 50% reduction in cell survival compared to the control cultured in parallel without drug) calculated by Microsoft Excel (2010).

**Fluorescent-based staining**

In order to confirm the cell death, the cells morphology changes were analyzed by the Acridine Orange/Ethidium Bromide double staining method. A number of 10^4 SW480 cells were seeded into each well of chamber slide (30118, SPL, Korea) and incubated for 24 h in a humidified, 5% CO₂ at 37 °C. The cells were treated with various concentration of metabolites, stained with 10 μl of Acridine Orange 50 mg mL}^{-1} (A6014, Sigma, Germany) and Ethidium Bromide 50 mg mL}^{-1} (E7637, Sigma, Germany) for 5 min and then washed with PBS. Ultimately, the cell death was characterized under a fluorescence microscope with 400× magnification.

**Flow cytometry analysis for cell cycle and apoptosis**

SW480 cells were treated with metabolites (100, 500, 1000 ng mL}^{-1}) for 48 h, the harvested cells were washed with ice-cold PBS, fixed in 70% (v/v) ethanol (100983, Merck, USA) and stored at 4°C for 1 h. Then the cells were transferred into PBS, incubated with 5μl (50 mg mL}^{-1}) RNase A for 30 min at 37°C, stained with 50 μg mL}^{-1} Propidium Iodide (11348639001, Sigma, Germany) for 5 min. Furthermore, the cell cycle profile was determined by BD FACS Calibur system and analyzed with FlowJo software. For evaluating apoptosis, harvested cells were permeabilized with Cytofix/Cytoperm (51-6896 KC, BD Bioscience, USA) solution in 4 °C for 20 min, washed with Perm/wash (51-6897 KC, BD Bioscience / USA) solution and incubated with monoclonal antibodies including Monoclonal Anti-Caspase 3 (51-68655X, eBioscience, USA) and Monoclonal Anti- Ki-67 (12-5699-42, eBioscience, USA) for 20 min. Consequently, the cells were washed with PBS and finally analyzed by BD FACSCalibur employing FlowJo software.

**Real time PCR**

SW480 cells were treated with 1000 ng mL}^{-1} of metabolites for 48 h. Total RNA were extracted by using RNX plus kit (RN7713 C, Sina Clon, IRAN) and 1μg of total RNA was transcribed reversely into single stranded cDNA using Bioneer cDNA synthesis kit (K-2261-6, Bioneer, Korea) according to manufacturer's instruction. RT-PCR was performed by utilizing the SYBR Green real-time PCR kit (7571540RXN, BD Bioscience, USA) in 14 μl reaction volume, which contained 7 μl of SYBR Green Master Mix PCR, 0/6 pmole form each forward and reverse primers (F: 5’- GTTCCGAGAGCTGAATGAGG-3’ and R: 5’-TTATGGCGGAGGCTAGACTG-3’), 1 μl of diluted cDNA template and 5/4 μl of DEPC treated water. The conditions for amplification of genes were in order: initial denaturation at 95 °C for 3 min, 40 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 60 s and elongation at 72 °C for 3 min. A quantitative real-time PCR was performed with Rotor-Gene 6000 and the relative gene expression level was determined by employing Rotor-Gene 6000 series software 1/7.

**Results and Discussion**

Streptomyces Levis ABRIINW111 induced apoptosis and reduced proliferation in SW480

Actinomycetes and their dominant genus *Streptomyces* sp. play an important roles as an anti-cancer agent. Recent studies reported anti-tumor activity of the *Streptomyces* sp. SY-103 metabolites by inducing apoptosis in Leukemia and Hela cells. The cytotoxicity effect of metabolites on SW480 cell line was determined by MTT assay. The viability of SW480 cells was decreased after treatment with 100, 500, 1000, 2000 and 5000 ng mL}^{-1} of metabolites in 24, 48 and 72 h. As indicated in (Figure 2a), metabolites inhibited the cells growth rate in a concentration and time-dependent manner. The cells viability in concentration of 5000 ng mL}^{-1} for 24, 48 and 72 h treatment was 36/25%, 18/75% and 12/25% respectively. The IC₅₀ value in 24, 48 and 72 h treatment was approximately 1100, 1000, 900 ng mL}^{-1}. Therefore, the cell viability was decreased significantly by the increasing of time and metabolites concentration (Figure 2a).

Half of the discovered bioactive secondary metabolites are derived from Actinomycetes which able to act as antibiotics and anti-tumor agents. Moreover, it was proved that *Streptomyces Levis ABRIINW111* inhibited cell growth in a concentration/time-dependent manner and the mentioned metabolite has anti-tumor activity against colon cancer. Cancer cells were incubated with metabolites in concentration of 100,500,1000 ng mL}^{-1} for 48 h and double staining was performed by Acridine Orange/Ethidium Bromide to analyze the morphological transformations by florescent microscopy (Figure 2b). Apoptotic changes were measured in concentration of 100, 500 and 1000 ng mL}^{-1} by plasma membrane blebbing. The concentration of 1000 ng mL}^{-1} increased the plasma membrane blebbing in SW480 cells significantly (Figure 2b).
Figure 2. Cell cytotoxicity was examined by MTT assay. (a) SW480 cells were incubated with the indicated concentrations of Streptomyces Levis metabolites for 24, 48 and 72 h (absorbance at a wavelength of 570-630 nm). (b) Morphology of SW480 cells after 48 h exposure to Metabolites of Streptomyces sp. ABRIINW111 was examined by fluorescent scope. Untreated cells (a) treated cells 100 ng/ml (b) treated cells 500 ng/ml (c) treated cells 1000 ng/ml (d). After 48 h, treated cells were revealed as the marked blebbing morphology. Values are expressed relatively to the control and as Mean ± SD of three independent experiments (P < 0.001).

The cell cycle was analyzed in sub G1, G1 and G2/M phases (Figure 3). Streptomyces Levis ABRIINW111 metabolites in concentration of 1000 ng ml⁻¹ increased G1 and G2/M phase whereas an average of S phase was reduced. However, subG1 phase increased from 2/6% in control to 11/8 % in treated cells. G1 phase reduced dramatically from 38/9% to 3/42 % in treated cells and also G2/M phase was 0/29% in treated cells and 10/9% in the control group (Figure 3). Therefore cell cycle analysis indicated that metabolites are able to increase subG1 phase (apoptosis) and cell cycle arrest in G1, G2/M and S phase as well.

Apoptosis is an active process that leads to cell death and is mediated by two extracellular and intracellular signaling pathways, where Caspases family is involved in both of them. In order to express the effects of metabolites on proliferation and apoptosis, proliferation (Ki-67 expression) and apoptosis (Caspase 3 expression) were evaluated by flow cytometry. In accordance with morphological changes, metabolites increased Caspase3 expression and reduced Ki67 expression in concentration dependent manner. After 48 h, Caspase3 level was 23/3%, 44/3%, 65/0% in concentration of 100, 500 and 1000 ng ml⁻¹ respectively, whereas in non-treated cells it was 7/69% and Ki-67 level in concentration of 100, 500 and 1000 ng ml⁻¹ was 92/4%, 72/7% and 44/4% respectively, but it was 95/6% in the control group (Figure 4).

Ki-67 expression is low in G1 phase and is increased during S and G2 phase and reached the highest expression in M phase. In cancer cells, Oncogene p53 is frequently mutated or overexpressed. Cancer cells presenting mutation or overexpression of oncogene P53 are an indication of higher rates of proliferation as measured by Ki-67.
Streptomyces Levis inhibits colon cancer

Figure 4. Streptomyces Levis ABRINW111 can alter the apoptosis and proliferation of colon cancer cells. SW480 was treated with indicated concentrations of metabolites for 48 h and was evaluated by flow cytometry (FACS) for Caspase3 and Ki-67 expression. (a) FACS profile of Caspase 3 expression: Control cells (a) 100 ng ml⁻¹ (b) 500 ng ml⁻¹ (c) 1000 ng ml⁻¹ (d). (b) Mean (SD) proportion of Caspase 3 expression with an indicated concentration of metabolites. (c) FACS profile of Ki67 expression: Control cells (a) 100 ng ml⁻¹ (b) 500 ng ml⁻¹ (c) 1000 ng ml⁻¹ (d). (d) Mean (SD) proportion of Ki67 expression with the indicated concentrations of metabolites. Values are demonstrated as mean ± SD from 4 independent experiments (P_Value <0.0001).

Streptomyces Levis ABRINW111 metabolites increased P53 gene expression in SW480 cells

Previous studies demonstrated that P53 has a relationship with both apoptosis and cell cycle. In order to examine P53 gene expression, a quantitative real-time PCR which followed the incubation of SW480 with 1000 ng ml⁻¹ Streptomyces Levis metabolites for 48 h was performed. P53 expression increased remarkably in treated cells around 3-fold in comparison with control cells (Figure 5).

P53 as a tumor suppressor gene is mutated in a wide variety of human malignancies. It encodes a transcription factor that regulates cellular responses to DNA damage, cell cycle progression, and genomic stability. P53-dependent cell cycle arrest can act through the Cdk inhibitor on P21. Based on several studies, following DNA damage, P53 and P21 mediate G1 and G2 phase of cell cycle will arrest. It was acknowledged that p21 transcription is induced in p53-infected cells. Metabolites might affect phosphorylation/dephosphorylation of Cdc2 and may lead to cell cycle arrest in G2/M phase. Metabolites inhibit topoisomerase II and can arrest the cell cycle in G2/M phase. In the present study, the subG1 phase was increased, whereas G1 phase and G2/M phase were decreased in the treated cells. These results indicated that metabolites could cause a delay in cell cycle at G2/M phase.

The induction of apoptosis with P53 is a major factor as tumor suppressor. Metabolites inducing apoptosis may be mediated by Bcl-2 family which either inhibit...
or activate apoptosis. Bax and Bad as pro-apoptotic effector genes stimulate realizing cytochrome C from the mitochondria which in turn will induce the activation of Caspases resulting in cell death.

Conclusion

The presented study demonstrated that Streptomyces Levis ABRIINW111 metabolites increased P53 gene expression and apoptosis significantly and reduced the proliferation in SW480 Colon cancer cell line as well. Additionally, the cell cycle was arrested in G$_1$ and G$_2$/M phase. Overall, Streptomyces Levis ABRIINW111 metabolites are a candidate for Colon cancer treatment.

Acknowledgments

Authors gratefully acknowledge Kobra Velaei, Soheila Montazersaheb, Mehdi rasouli and Dariush Shanehbandi for the technical support. The current study was supported by Research Council of Tabriz University of Medical Sciences (grant 5/104/1236).

Ethical Issues

The current article does not contain any studies with human or animal subjects.

Conflict of Interest

All authors declared that there is no conflict of interest.

References

1. Arber N, Levin B. Chemoprevention of colorectal cancer: Ready for routine use? Recent Results Cancer Res 2005;166:213-30. doi: 10.2174/1568026054201659

2. Rodriguez M, Du GJ, Wang CZ, Yuan CS. Letter to the editor: Panaxadiol's anticancer activity is enhanced by epicatechin. Am J Chin Med 2010; 38(6):1233-5. doi: 10.1142/S0192415X10008597

3. Yang K, Kurihara N, Fan K, Newmark H, Rigas B, Bancroft L, et al. Dietary induction of colonic tumors in a mouse model of sporadic colon cancer. Cancer Res 2008; 68(19):7803-10. doi: 10.1158/0008-5472.CAN-08-1209

4. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH, Lipkin M. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin d in c57bl/6 mice: A preclinical model for human sporadic colon cancer. Carcinogenesis 2009; 30(1):88-92. doi: 10.1093/carcin/bgn229

5. Suriy Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 1999; 428(1-2):305-27.

6. Xie G, Zhu X, Li Q, Gu M, He Z, Wu J, et al. Sz-685c, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the akt/fork pathway. Br J Pharmacol 2010; 159(3):689-97. doi: 10.1111/j.1476-5381.2009.00577.x

7. Ganesan A. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 2008; 12(3):306-17. doi: 10.1016/j.cbpa.2008.03.016

8. Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT, Prinsep MR. Marine natural products. Nat Prod Rep 2007; 24(1):31-86. doi: 10.1039/b603047p

9. Cragg GM, Kingston DG, Newman DJ. Anticancer agents from natural products. 2nd ed. England: Taylor & Francis Group (CRC press); 2011.

10. Huang S, Houghton PJ. Resistance to rapamycin: A novel anticancer drug. Cancer Metastasis Rev 2001; 20(1-2):69-78.

11. Jeong SY, Han MH, Jin CY, Kim KY, Choi BT, Nam TJ, et al. Apoptosis induction of human leukemia cells by streptomyces sp. SY-103 metabolites through activation of caspase-3 and inactivation of Akt. Int J Mol Med 2010;25(1):31-40. doi: 10.3892/ijmm_00000310

12. Fatourachi P, Faramarziyan Azimi Maragheh B, Mohammadi SM, Valipour B, Dehnad A, Nozad Charoudeh H. Extracted metabolite from streptomyces Levis abriinw111 altered the gene expression in colon cancer. Gastroenterol Hepatol Bed Bench 2018; 11(1):34-41.

13. Wong RS. Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res 2011; 30:87. doi: 10.1186/1756-9966-30-87

14. O'Brien MA, Kirby R. Apoptosis: A review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care 2008;18(6):572-85. doi: 10.1111/j.1476-4431.2008.00363.x

15. Bellamy CO. P53 and apoptosis. Brit Med Bull 1997;53(3):522-38. doi: 10.1093/oxfordjournals.bmb.0011628

16. Russo A, Terrasi M, Agnese V, Santini D, Bazan V. Apoptosis: A relevant tool for anticancer therapy. Ann...
Streptomyces Levis inhibits colon cancer

Oncol 2006; 17(suppl 7):vii115-vii23. doi: 10.1093/annonc/mdi963

17. Sadigh-Eteghad S, Dehnad A, Shanebandi D, Khalili I, Razmarayi N, Namvaran A. Identification and characterization of a streptomyces sp. Isolate exhibiting activity against multidrug-resistant coagulase-negative staphylococci. *Vet Res Commun* 2011; 35(8):477-86. doi: 10.1007/s11259-011-9491-9

18. Berdy J. Bioactive microbial metabolites. *J Antibiot (Tokyo)* 2005; 58(1):1-26. doi: 10.1038/ja.2005.1

19. Demain AL, Sanchez S. Microbial drug discovery: 80 years of progress. *J Antibiot (Tokyo)* 2009; 62(1):5-16. doi: 10.1038/ja.2008.16

20. Lee CH, Lim H, Moon S, Shin C, Kim S, Kim BJ, et al. Novel anticancer agent, benzylidihydroxyoctenone, isolated from streptomyces sp. Causes g1 cell cycle arrest and induces apoptosis of hela cells. *Cancer Sci* 2007; 98(6):795-802. doi: 10.1111/j.1349-7006.2007.00473.x

21. Blunt JW, Copp BR, Munro MH, Northcote PT, Prinsep MR. Marine natural products. *Nat Prod Rep* 2006; 23(1):26-78. doi: 10.1039/b502792f

22. Mann J. Natural products as immunosuppressive agents. *Nat Prod Rep* 2001; 18(4):417-30.

23. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. *Pharmacol Ther* 2001; 92(1):57-70.

24. Endl E, Hollmann C, Gerdes J. Antibodies against the ki-67 protein: Assessment of the growth fraction and tools for cell cycle analysis. *Methods Cell Biol* 2001;63:399-418.

25. Schwarting R, Gerdes J, Niehus J, Jaeschke L, Stein H. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody ki-67. *J Immunol Methods* 1986; 90(1):65-70.

26. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by ki-67 antibody in hl-60 cells. *Cell Prolif* 1992;25(1):31-40.

27. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E. Effect of tamoxifen on ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. *Br J Cancer* 1993; 67(3):606-11.

28. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. *J Clin Oncol* 1999; 17(10):3058-63. doi: 10.1200/jco.1999.17.10.3058

29. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, TITLEY JC, et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. *Breast Cancer Res Treat* 1998; 48(1):11-20.

30. Dardes RD, Horiguchi J, Jordan VC. A pilot study of the effects of short-term tamoxifen therapy on ki-67 labelling index in women with primary breast cancer. *Int J Oncol* 2000; 16(1):25-30.

31. Ellis P, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, et al. Reduced apoptosis and proliferation and increased bc-2 in residual breast cancer following preoperative chemotherapy. *Breast Cancer Res Treat* 1998; 48(2):107-16.

32. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, et al. Effect of neoadjuvant chemotherapy on ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. *Anticancer Res* 1996; 16(5B):3105-10.

33. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, et al. Relationship between tumour shrinkage and reduction in ki67 expression after primary chemotherapy in human breast cancer. *Br J Cancer* 2001; 85(8):1106-12. doi: 10.1054/bjoc.2001.2048

34. Lipponen P. Apoptosis in breast cancer: Relationship with other pathological parameters. *Endocr Relat Cancer* 1999; 6(1):13-6.

35. Liu S, Edgerton SM, Moore DH 2nd, Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. *Clin Cancer Res* 2001;7(6):1716-23.

36. Beck T, Weller EE, Weikl W, Brumm C, Wilkens C, Knapstein PG. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: Correlations with established prognosis parameters and with the proliferation marker, miB1. *Gynecol Oncol* 1995; 57(1):96-104. doi: 10.1006/gyno.1995.1104

37. Pinder SE, Wenczyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker miB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. *Br J Cancer* 1995; 71(1):146-9

38. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. *Science* 1991; 253(5015):49-53.

39. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. *Nature* 1991; 351(6326):453-6. doi: 10.1038/351453a0

40. Levine AJ. P53, the cellular gatekeeper for growth and division. *Cell* 1997; 88(3):323-31.

41. Hartwell LH, Kastan MB. Cell cycle control and cancer. *Science* 1994; 266(5192):1821-8.

42. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev* 1995; 9(10):1149-63.

43. Gautier J, Matsukawa T, Nurse P, Maller J. Dephosphorylation and activation of xenopusp34cdc2 protein kinase during the cell cycle. *Nature* 1989; 339(6226):626–629. doi: 10.1038/339626a0

44. Morla AO, Draetta G, Beach D, Wang JY. Dephosphorylation and activation of xenopusp34cdc2 protein kinase during the cell cycle. *Science* 1997; 266(5192):1821-8.

45. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev* 1995; 9(10):1149-63.

46. Gautier J, Matsukawa T, Nurse P, Maller J. Dephosphorylation and activation of xenopusp34cdc2 protein kinase during the cell cycle. *Nature* 1989; 339(6226):626–629. doi: 10.1038/339626a0

47. Morla AO, Draetta G, Beach D, Wang JY. Reversible tyrosine phosphorylation of cdc2: Dephosphorylation accompanies activation during entry into mitosis. *Cell* 1995; 58(1):193-203.

48. Guilford KL, Nurse P. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. *Nature* 1989; 342(6245):39-45. doi: 10.1038/342039a0
46. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. *J Biol Chem* 1984; 259(21):13550-6.

47. Gottlieb TM, Oren M. P53 and apoptosis. *Semin Cancer Biol* 1998;8(5):359-368.

48. Nagata S. Apoptosis by death factor. *Cell* 1997; 88(3):355-65.

49. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. *Cell* 1994; 79(2):329-39.

50. Thees S, Hubbard GB, Winckler J, Schultz C, Rami A. Specific alteration of the bax/bcl2 ratio and cytochrome c without execution of apoptosis in the hippocampus of aged baboons. *Restor Neurol Neurosci* 2005; 23(1):1-9.